Bartter syndrome type 3 is an inherited renal tubulopathy of autosomal recessive inheritance caused by biallelic variants in the CLCNKB gene. This gene encodes the ClC-Kb chloride channel, which is necessary for salt reabsorption in distal segments of the nephron. Its dysfunction causes renal loss of chloride, sodium, and water, with hypokalemia, metabolic alkalosis, and normal or low blood pressure.
Bartter syndrome type 3
The CLCNKB gene provides instructions for making a chloride channel called ClC-Kb, which belongs to the CLC family. This channel is mainly expressed in the thick ascending limb of the loop of Henle, the distal convoluted tubule, and other renal segments, where it facilitates the basolateral exit of chloride from tubular cells into the bloodstream. This process is essential for the kidney to properly reabsorb sodium chloride and maintain water and electrolyte balance.
When pathogenic variants in CLCNKB exist, the ClC-Kb channel is either dysfunctional or absent. This results in chronic renal salt loss, activation of the renin-angiotensin-aldosterone system, hypokalemia, hypochloremia, and metabolic alkalosis. Bartter syndrome type 3 is one of the most frequent subtypes and presents with significant clinical heterogeneity: it can manifest as a neonatal or classic form of Bartter, but also as a milder phenotype resembling Gitelman syndrome, with hypomagnesemia and hypocalciuria in some patients. Inheritance is autosomal recessive, meaning an affected individual must inherit an altered copy of the gene from each parent. The overall incidence of Bartter syndrome is low, estimated at approximately 1 in 1,000,000 live births, though recurrent or founder variants exist in some populations.
Symptoms
The age of onset of Bartter syndrome type 3 is variable, ranging from the neonatal period to late childhood or adulthood. The most frequent symptoms include polyuria, polydipsia, recurrent dehydration, vomiting, muscle weakness, cramps, and growth retardation in infancy. Laboratory findings typically include hypokalemia, metabolic alkalosis, elevated renin and aldosterone levels, and normal or low blood pressure. Some patients present with a neonatal picture of prematurity or polyhydramnios, while others have milder, later symptoms, with biochemical features similar to Gitelman syndrome.
Disease management
Management focuses on preventing dehydration and consistently correcting electrolyte disturbances. Treatment usually includes oral potassium and sodium supplements, adequate fluid intake, and, in some cases, magnesium. Nonsteroidal anti-inflammatory drugs, such as indomethacin or ibuprofen, can be used to reduce renal salt loss, always with monitoring for possible gastrointestinal and renal effects. In certain patients, potassium-sparing drugs, such as spironolactone, eplerenone, or amiloride, are added. Follow-up should include periodic monitoring of growth, blood pressure, electrolytes, renal function, and complications such as nephrocalcinosis or chronic kidney disease. Family genetic counseling is recommended.
Genes analyzed
Bibliography
García-Castaño A, Gómez-Conde S, Gondra L, et al. Genotypic variability in patients with clinical diagnosis of Bartter syndrome type 3. Sci Rep. 2023 Aug 3;13(1):12587.
Seys E, Andrini O, Keck M, et al. Clinical and Genetic Spectrum of Bartter Syndrome Type 3. J Am Soc Nephrol. 2017 Aug;28(8):2540-2552.
Han Y, Cheng H, Shao S, et al. Thirteen novel CLCNKB variants and genotype/phenotype association study in 42 Chinese patients with Bartter syndrome type 3. Endocrine. 2020 Apr;68(1):192-202.
